Welcome to drugdiscoveryanddevelopment.co.uk
Click to listen highlighted text!
Welcome to drugdiscoveryanddevelopment.co.uk
Subscribe to newsletter
Facebook
Linkedin
X
Youtube
Linkedin
Twitter
Youtube
Tue 22 September 2026
A Pharma Press Global company
Subscribe to DDD newsletter
Search
Drug Discovery and Development
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Finance
Conferences
Journal
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
8 September 2026
Products
CDMO
CRO
Home
Authors
Posts by Editor
Editor
162 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Finance, mergers and appointments
Pain pipeline investment by Eli Lilly
Editor
-
12 June 2025
0
Finance, mergers and appointments
Biotech giant announces closure of $65m public offering
Editor
-
2 June 2025
0
1
...
15
16
17
Page 17 of 17
TOP AUTHORS
Editor
162 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Julian English
36 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Most Read
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Click to listen highlighted text!